Inclusion Criteria:

- Pathologically confirmed Stage IIIB NSCLC with malignant pleural effusion, or Stage
IV disease

- Measurable disease on CT scan (by the RECIST criteria)

- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 (which means
able to independently care for self and to perform light work) .

- Adequate blood counts

- Adequate liver and kidney function

- Subjects or their legal representatives must be able to read, understand and provide
written informed consent to participate in the trial.

Exclusion Criteria:

- Predominant Squamous Cell NSCLC histology.

- History of treatment for NSCLC with chemotherapy, biological therapy, immunotherapy
(surgery or radiation therapy are accepted)

- Brain (CNS) metastasis by head CT scan or MRI

- Subjects with history of prior malignancy except for curatively treated basal cell
carcinoma of the skin; cervical intra-epithelial neoplasia; or localized prostate
cancer with a current prostate specific antigen (PSA) of < 4.0 mg/dL. Subjects with
other curatively treated malignancies who have no evidence of metastatic disease and
>2 year disease free interval may be entered after discussion with the Medical
Monitor.

- History of bleeding disorders, particularly coughing up ≥ ½ teaspoon bright red blood
during the last 3 months

- Certain cardiac disorders such as recent myocardial infarction (MI), severe
congestive heart failure, certain types of abnormal cardiac rhythm

- Uncontrolled high blood pressure despite medications

- Uncontrolled, clinically significant active infection.

- Known HIV

- Known hypersensitivity to any of the components of CA4P, paclitaxel, carboplatin,
bevacizumab, or radiologic contrast dyes.

Details of the above and additional inclusion and exclusion criteria can be discussed with
an investigator.